How Regulatory-ready Biosimulation Advances Pre-clinical and Clinical CNS Drug Development

Time: 11:45 am
day: Day One: Track B AM


  • Predict dose-response relationship between administered viral load and target protein expression
  • For Gene Therapy and Neurological Diseases, these tools increase confidence around dosing, immunogenicity, and special populations
  • QSP modeling using virtual patients/trials supported by global regulators